ID   MITF_HUMAN              Reviewed;         526 AA.
AC   O75030; B4DJL2; D3K197; E9PFN0; Q14841; Q9P2V0; Q9P2V1; Q9P2V2;
AC   Q9P2Y8;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   21-FEB-2001, sequence version 2.
DT   22-JUL-2015, entry version 162.
DE   RecName: Full=Microphthalmia-associated transcription factor;
DE   AltName: Full=Class E basic helix-loop-helix protein 32;
DE            Short=bHLHe32;
GN   Name=MITF; Synonyms=BHLHE32;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A2), AND NUCLEOTIDE SEQUENCE
RP   [MRNA] OF 1-35 (ISOFORMS H1/H2).
RC   TISSUE=Kidney;
RX   PubMed=9647758; DOI=10.1006/bbrc.1998.8838;
RA   Amae S., Fuse N., Yasumoto K., Sato S., Yajima I., Yamamoto H.,
RA   Udono T., Durlu Y.K., Tamai M., Takahashi K., Shibahara S.;
RT   "Identification of a novel isoform of microphthalmia-associated
RT   transcription factor that is enriched in retinal pigment epithelium.";
RL   Biochem. Biophys. Res. Commun. 247:710-715(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM M1).
RC   TISSUE=Skin;
RX   PubMed=8069297; DOI=10.1093/hmg/3.4.553;
RA   Tachibana M., Perez-Jurado L.A., Nakayama A., Hodgkinson C.A., Li X.,
RA   Schneider M., Miki T., Fex J., Francke U., Arnheiter H.;
RT   "Cloning of MITF, the human homolog of the mouse microphthalmia gene
RT   and assignment to chromosome 3p14.1-p12.3.";
RL   Hum. Mol. Genet. 3:553-557(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MDEL), AND TISSUE SPECIFICITY.
RX   PubMed=20163701; DOI=10.1186/1741-7015-8-14;
RA   Wang Y., Radfar S., Liu S., Riker A.I., Khong H.T.;
RT   "Mitf-Mdel, a novel melanocyte/melanoma-specific isoform of
RT   microphthalmia-associated transcription factor-M, as a candidate
RT   biomarker for melanoma.";
RL   BMC Med. 8:14-14(2010).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A2).
RC   TISSUE=Uterus;
RX   PubMed=11230166; DOI=10.1101/gr.GR1547R;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H.,
RA   Lauber J., Duesterhoeft A., Beyer A., Koehrer K., Strack N.,
RA   Mewes H.-W., Ottenwaelder B., Obermaier B., Tampe J., Heubner D.,
RA   Wambutt R., Korn B., Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and
RT   analysis of 500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 12).
RC   TISSUE=Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS M1 AND M2).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS A1/A2; B1/B2;
RP   H1/H2 AND M1/M2).
RX   PubMed=10760582; DOI=10.1016/S0167-4781(00)00051-8;
RA   Udono T., Yasumoto K., Takeda K., Amae S., Watanabe K., Saito H.,
RA   Fuse N., Tachibana M., Takahashi K., Tamai M., Shibahara S.;
RT   "Structural organization of the human microphthalmia-associated
RT   transcription factor gene containing four alternative promoters.";
RL   Biochim. Biophys. Acta 1491:205-219(2000).
RN   [9]
RP   ALTERNATIVE SPLICING (ISOFORM C1/C2).
RC   TISSUE=Kidney;
RX   PubMed=10578055; DOI=10.1093/oxfordjournals.jbchem.a022548;
RA   Fuse N., Yasumoto K., Takeda K., Amae S., Yoshizawa M., Udono T.,
RA   Takahashi K., Tamai M., Tomita Y., Tachibana M., Shibahara S.;
RT   "Molecular cloning of cDNA encoding a novel microphthalmia-associated
RT   transcription factor isoform with a distinct amino-terminus.";
RL   J. Biochem. 126:1043-1051(1999).
RN   [10]
RP   PHOSPHORYLATION AT SER-180 AND SER-516, UBIQUITINATION, AND
RP   MUTAGENESIS OF SER-180 AND SER-516.
RX   PubMed=10673502;
RA   Wu M., Hemesath T.J., Takemoto C.M., Horstmann M.A., Wells A.G.,
RA   Price E.R., Fisher D.Z., Fisher D.E.;
RT   "c-Kit triggers dual phosphorylations, which couple activation and
RT   degradation of the essential melanocyte factor Mi.";
RL   Genes Dev. 14:301-312(2000).
RN   [11]
RP   FUNCTION, MUTAGENESIS OF SER-405, AND PHOSPHORYLATION AT SER-405.
RX   PubMed=10587587; DOI=10.1093/hmg/9.1.125;
RA   Takeda K., Takemoto C., Kobayashi I., Watanabe A., Nobukuni Y.,
RA   Fisher D.E., Tachibana M.;
RT   "Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is a
RT   phosphorylation site with functional significance.";
RL   Hum. Mol. Genet. 9:125-132(2000).
RN   [12]
RP   INTERACTION WITH KARS.
RX   PubMed=14975237; DOI=10.1016/S1074-7613(04)00020-2;
RA   Lee Y.N., Nechushtan H., Figov N., Razin E.;
RT   "The function of lysyl-tRNA synthetase and Ap4A as signaling
RT   regulators of MITF activity in FcepsilonRI-activated mast cells.";
RL   Immunity 20:145-151(2004).
RN   [13]
RP   SUMOYLATION AT LYS-289 AND LYS-423, AND MUTAGENESIS OF LYS-289 AND
RP   LYS-423.
RX   PubMed=15507434; DOI=10.1074/jbc.M411757200;
RA   Miller A.J., Levy C., Davis I.J., Razin E., Fisher D.E.;
RT   "Sumoylation of MITF and its related family members TFE3 and TFEB.";
RL   J. Biol. Chem. 280:146-155(2005).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-414, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-414, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-491, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   INVOLVEMENT IN CMM8, AND VARIANT LYS-425.
RX   PubMed=22012259; DOI=10.1038/nature10539;
RA   Bertolotto C., Lesueur F., Giuliano S., Strub T., de Lichy M.,
RA   Bille K., Dessen P., d'Hayer B., Mohamdi H., Remenieras A., Maubec E.,
RA   de la Fouchardiere A., Molinie V., Vabres P., Dalle S., Poulalhon N.,
RA   Martin-Denavit T., Thomas L., Andry-Benzaquen P., Dupin N.,
RA   Boitier F., Rossi A., Perrot J.L., Labeille B., Robert C.,
RA   Escudier B., Caron O., Brugieres L., Saule S., Gardie B., Gad S.,
RA   Richard S., Couturier J., Teh B.T., Ghiorzo P., Pastorino L., Puig S.,
RA   Badenas C., Olsson H., Ingvar C., Rouleau E., Lidereau R.,
RA   Bahadoran P., Vielh P., Corda E., Blanche H., Zelenika D., Galan P.,
RA   Aubin F., Bachollet B., Becuwe C., Berthet P., Bignon Y.J.,
RA   Bonadona V., Bonafe J.L., Bonnet-Dupeyron M.N., Cambazard F.,
RA   Chevrant-Breton J., Coupier I., Dalac S., Demange L., d'Incan M.,
RA   Dugast C., Faivre L., Vincent-Fetita L., Gauthier-Villars M.,
RA   Gilbert B., Grange F., Grob J.J., Humbert P., Janin N., Joly P.,
RA   Kerob D., Lasset C., Leroux D., Levang J., Limacher J.M.,
RA   Livideanu C., Longy M., Lortholary A., Stoppa-Lyonnet D., Mansard S.,
RA   Mansuy L., Marrou K., Mateus C., Maugard C., Meyer N., Nogues C.,
RA   Souteyrand P., Venat-Bouvet L., Zattara H., Chaudru V., Lenoir G.M.,
RA   Lathrop M., Davidson I., Avril M.F., Demenais F., Ballotti R.,
RA   Bressac-de Paillerets B.;
RT   "A SUMOylation-defective MITF germline mutation predisposes to
RT   melanoma and renal carcinoma.";
RL   Nature 480:94-98(2011).
RN   [18]
RP   INVOLVEMENT IN CMM8, VARIANT LYS-425, AND CHARACTERIZATION OF VARIANT
RP   LYS-425.
RX   PubMed=22080950; DOI=10.1038/nature10630;
RA   Yokoyama S., Woods S.L., Boyle G.M., Aoude L.G., MacGregor S.,
RA   Zismann V., Gartside M., Cust A.E., Haq R., Harland M., Taylor J.C.,
RA   Duffy D.L., Holohan K., Dutton-Regester K., Palmer J.M., Bonazzi V.,
RA   Stark M.S., Symmons J., Law M.H., Schmidt C., Lanagan C., O'Connor L.,
RA   Holland E.A., Schmid H., Maskiell J.A., Jetann J., Ferguson M.,
RA   Jenkins M.A., Kefford R.F., Giles G.G., Armstrong B.K., Aitken J.F.,
RA   Hopper J.L., Whiteman D.C., Pharoah P.D., Easton D.F., Dunning A.M.,
RA   Newton-Bishop J.A., Montgomery G.W., Martin N.G., Mann G.J.,
RA   Bishop D.T., Tsao H., Trent J.M., Fisher D.E., Hayward N.K.,
RA   Brown K.M.;
RT   "A novel recurrent mutation in MITF predisposes to familial and
RT   sporadic melanoma.";
RL   Nature 480:99-103(2011).
RN   [19]
RP   IDENTIFICATION IN A COMPLEX WITH HINT1 AND CTNNB1, AND FUNCTION.
RX   PubMed=22647378; DOI=10.4161/cc.20765;
RA   Genovese G., Ghosh P., Li H., Rettino A., Sioletic S., Cittadini A.,
RA   Sgambato A.;
RT   "The tumor suppressor HINT1 regulates MITF and beta-catenin
RT   transcriptional activity in melanoma cells.";
RL   Cell Cycle 11:2206-2215(2012).
RN   [20]
RP   VARIANTS WS2A LYS-310; ARG-324 DEL; PRO-357; ASP-385 AND PRO-405.
RX   PubMed=8589691; DOI=10.1093/hmg/4.11.2131;
RA   Tassabehji M., Newton V.E., Liu X.-Z., Brady A., Donnai D.,
RA   Krajewska-Walasek M., Murday V., Norman A., Obersztyn E., Reardon W.,
RA   Rice J.C., Trembath R., Wieacker P., Whiteford M., Winter R.,
RA   Read A.P.;
RT   "The mutational spectrum in Waardenburg syndrome.";
RL   Hum. Mol. Genet. 4:2131-2137(1995).
RN   [21]
RP   VARIANT TIETZS LYS-317.
RC   TISSUE=Blood;
RX   PubMed=10851256; DOI=10.1136/jmg.37.6.446;
RA   Smith S.D., Kelley P.M., Kenyon J.B., Hoover D.;
RT   "Tietz syndrome (hypopigmentation/deafness) caused by mutation of
RT   MITF.";
RL   J. Med. Genet. 37:446-448(2000).
CC   -!- FUNCTION: Transcription factor that regulates the expression of
CC       genes with essential roles in cell differentiation, proliferation
CC       and survival. Binds to symmetrical DNA sequences (E-boxes) (5'-
CC       CACGTG-3') found in the promoters of target genes, such as BCL2
CC       and tyrosinase (TYR). Plays an important role in melanocyte
CC       development by regulating the expression of tyrosinase (TYR) and
CC       tyrosinase-related protein 1 (TYRP1). Plays a critical role in the
CC       differentiation of various cell types, such as neural crest-
CC       derived melanocytes, mast cells, osteoclasts and optic cup-derived
CC       retinal pigment epithelium. {ECO:0000269|PubMed:10587587,
CC       ECO:0000269|PubMed:22647378}.
CC   -!- SUBUNIT: Efficient DNA binding requires dimerization with another
CC       bHLH protein. Binds DNA in the form of homodimer or heterodimer
CC       with either TFE3, TFEB or TFEC. Interacts with KARS. Identified in
CC       a complex with HINT1 and CTNNB1. {ECO:0000269|PubMed:14975237,
CC       ECO:0000269|PubMed:22647378}.
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=12;
CC         Comment=The X2-type isoforms differ from the X1-type isoforms by
CC         the absence of a 6 residue insert.;
CC       Name=A1;
CC         IsoId=O75030-1; Sequence=Displayed;
CC       Name=A2;
CC         IsoId=O75030-2; Sequence=VSP_002128;
CC       Name=B1;
CC         IsoId=O75030-3; Sequence=VSP_002124;
CC       Name=B2;
CC         IsoId=O75030-4; Sequence=VSP_002124, VSP_002128;
CC       Name=C1;
CC         IsoId=O75030-5; Sequence=VSP_002125;
CC       Name=C2;
CC         IsoId=O75030-6; Sequence=VSP_002125, VSP_002128;
CC       Name=H1;
CC         IsoId=O75030-7; Sequence=VSP_002126;
CC       Name=H2;
CC         IsoId=O75030-8; Sequence=VSP_002126, VSP_002128;
CC       Name=M1;
CC         IsoId=O75030-9; Sequence=VSP_002127;
CC       Name=M2;
CC         IsoId=O75030-10; Sequence=VSP_002127, VSP_002128;
CC       Name=Mdel;
CC         IsoId=O75030-11; Sequence=VSP_002127, VSP_045178, VSP_045179;
CC       Name=12;
CC         IsoId=O75030-12; Sequence=VSP_046438, VSP_045179;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Isoform M is exclusively expressed in
CC       melanocytes and melanoma cells. Isoform A and isoform H are widely
CC       expressed in many cell types including melanocytes and retinal
CC       pigment epithelium (RPE). Isoform C is expressed in many cell
CC       types including RPE but not in melanocyte-lineage cells. Isoform
CC       Mdel is widely expressed in melanocytes, melanoma cell lines and
CC       tissues, but almost undetectable in non-melanoma cell lines.
CC       {ECO:0000269|PubMed:20163701}.
CC   -!- PTM: Phosphorylation at Ser-405 significantly enhances the ability
CC       to bind the tyrosinase promoter. Phosphorylated at Ser-180 and
CC       Ser-516 following KIT signaling, trigerring a short live
CC       activation: Phosphorylation at Ser-180 and Ser-516 by MAPK and
CC       RPS6KA1, respectively, activate the transcription factor activity
CC       but also promote ubiquitination and subsequent degradation by the
CC       proteasome. {ECO:0000269|PubMed:10587587,
CC       ECO:0000269|PubMed:10673502}.
CC   -!- PTM: Ubiquitinated following phosphorylation at Ser-180, leading
CC       to subsequent degradation by the proteasome. Deubiquitinated by
CC       USP13, preventing its degradation. {ECO:0000269|PubMed:10673502}.
CC   -!- DISEASE: Waardenburg syndrome 2A (WS2A) [MIM:193510]: WS2 is a
CC       genetically heterogeneous, autosomal dominant disorder
CC       characterized by sensorineural deafness, pigmentary disturbances,
CC       and absence of dystopia canthorum. The frequency of deafness is
CC       higher in WS2 than in WS1. {ECO:0000269|PubMed:8589691}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Waardenburg syndrome 2, with ocular albinism, autosomal
CC       recessive (WS2-OA) [MIM:103470]: A disorder characterized by the
CC       association of features typical of Waardenburg syndrome type 2
CC       with ocular albinism. Patients manifest reduced visual acuity,
CC       albinotic fundus, deafness, hypomelanosis. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Tietz syndrome (TIETZS) [MIM:103500]: Autosomal dominant
CC       disorder characterized by generalized hypopigmentation and
CC       profound, congenital, bilateral deafness. Penetrance is complete.
CC       {ECO:0000269|PubMed:10851256}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Melanoma, cutaneous malignant 8 (CMM8) [MIM:614456]: A
CC       malignant neoplasm of melanocytes, arising de novo or from a pre-
CC       existing benign nevus, which occurs most often in the skin but
CC       also may involve other sites. {ECO:0000269|PubMed:22012259,
CC       ECO:0000269|PubMed:22080950}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the MiT/TFE family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 bHLH (basic helix-loop-helix) domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00981}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB006909; BAA32288.1; -; mRNA.
DR   EMBL; AB006989; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; Z29678; CAA82775.1; -; mRNA.
DR   EMBL; GU355676; ADB90411.1; -; mRNA.
DR   EMBL; AL110195; CAB53672.1; -; mRNA.
DR   EMBL; AK296129; BAG58874.1; -; mRNA.
DR   EMBL; AC099326; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104445; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104449; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC124915; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC026961; AAH26961.1; -; mRNA.
DR   EMBL; BC065243; AAH65243.1; -; mRNA.
DR   EMBL; AF034755; AAC39639.1; -; Genomic_DNA.
DR   EMBL; AB032359; BAA95208.1; -; Genomic_DNA.
DR   EMBL; AB032358; BAA95207.1; -; Genomic_DNA.
DR   EMBL; AB032357; BAA95206.1; -; Genomic_DNA.
DR   EMBL; AB009608; BAA95209.1; ALT_TERM; Genomic_DNA.
DR   CCDS; CCDS2913.1; -. [O75030-9]
DR   CCDS; CCDS43106.1; -. [O75030-2]
DR   CCDS; CCDS43107.1; -. [O75030-10]
DR   CCDS; CCDS46865.1; -. [O75030-8]
DR   CCDS; CCDS46866.2; -. [O75030-11]
DR   CCDS; CCDS54607.1; -. [O75030-12]
DR   PIR; I38024; I38024.
DR   PIR; T14752; T14752.
DR   RefSeq; NP_000239.1; NM_000248.3. [O75030-9]
DR   RefSeq; NP_001171896.1; NM_001184967.1. [O75030-12]
DR   RefSeq; NP_006713.1; NM_006722.2. [O75030-6]
DR   RefSeq; NP_937801.1; NM_198158.2. [O75030-10]
DR   RefSeq; NP_937802.1; NM_198159.2. [O75030-2]
DR   RefSeq; NP_937820.1; NM_198177.2. [O75030-8]
DR   RefSeq; NP_937821.2; NM_198178.2. [O75030-11]
DR   RefSeq; XP_005264811.1; XM_005264754.1. [O75030-1]
DR   RefSeq; XP_005264812.1; XM_005264755.2. [O75030-7]
DR   UniGene; Hs.166017; -.
DR   UniGene; Hs.618266; -.
DR   PDB; 4C7N; X-ray; 2.10 A; A=357-403.
DR   PDBsum; 4C7N; -.
DR   ProteinModelPortal; O75030; -.
DR   SMR; O75030; 312-402.
DR   BioGrid; 110432; 24.
DR   DIP; DIP-59573N; -.
DR   IntAct; O75030; 4.
DR   MINT; MINT-7997258; -.
DR   STRING; 9606.ENSP00000295600; -.
DR   ChEMBL; CHEMBL1741165; -.
DR   PhosphoSite; O75030; -.
DR   BioMuta; MITF; -.
DR   MaxQB; O75030; -.
DR   PaxDb; O75030; -.
DR   PRIDE; O75030; -.
DR   Ensembl; ENST00000314557; ENSP00000324246; ENSG00000187098. [O75030-10]
DR   Ensembl; ENST00000314589; ENSP00000324443; ENSG00000187098. [O75030-8]
DR   Ensembl; ENST00000328528; ENSP00000327867; ENSG00000187098. [O75030-6]
DR   Ensembl; ENST00000352241; ENSP00000295600; ENSG00000187098. [O75030-2]
DR   Ensembl; ENST00000394351; ENSP00000377880; ENSG00000187098. [O75030-9]
DR   Ensembl; ENST00000448226; ENSP00000391803; ENSG00000187098.
DR   Ensembl; ENST00000472437; ENSP00000418845; ENSG00000187098. [O75030-12]
DR   Ensembl; ENST00000531774; ENSP00000435909; ENSG00000187098. [O75030-11]
DR   GeneID; 4286; -.
DR   KEGG; hsa:4286; -.
DR   UCSC; uc003dnz.3; human. [O75030-2]
DR   UCSC; uc003doa.3; human. [O75030-6]
DR   UCSC; uc003dob.3; human. [O75030-8]
DR   UCSC; uc003doe.3; human. [O75030-10]
DR   UCSC; uc003dof.3; human. [O75030-9]
DR   UCSC; uc021xam.1; human.
DR   CTD; 4286; -.
DR   GeneCards; GC03P069788; -.
DR   HGNC; HGNC:7105; MITF.
DR   HPA; CAB002578; -.
DR   HPA; HPA003259; -.
DR   MIM; 103470; phenotype.
DR   MIM; 103500; phenotype.
DR   MIM; 156845; gene.
DR   MIM; 193510; phenotype.
DR   MIM; 614456; phenotype.
DR   neXtProt; NX_O75030; -.
DR   Orphanet; 404511; Clear cell papillary renal cell carcinoma.
DR   Orphanet; 293822; MITF-related melanoma and renal cell carcinoma predisposition syndrome.
DR   Orphanet; 352740; Ocular albinism with congenital sensorineural deafness.
DR   Orphanet; 319298; Papillary renal cell carcinoma.
DR   Orphanet; 42665; Tietz syndrome.
DR   Orphanet; 895; Waardenburg syndrome type 2.
DR   PharmGKB; PA30823; -.
DR   eggNOG; NOG251286; -.
DR   GeneTree; ENSGT00390000004402; -.
DR   HOGENOM; HOG000231368; -.
DR   HOVERGEN; HBG006768; -.
DR   InParanoid; O75030; -.
DR   KO; K09455; -.
DR   OMA; VLENCNQ; -.
DR   OrthoDB; EOG72G182; -.
DR   PhylomeDB; O75030; -.
DR   TreeFam; TF317174; -.
DR   SignaLink; O75030; -.
DR   GeneWiki; Microphthalmia-associated_transcription_factor; -.
DR   GenomeRNAi; 4286; -.
DR   NextBio; 16861; -.
DR   PMAP-CutDB; O75030; -.
DR   PRO; PR:O75030; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; O75030; -.
DR   CleanEx; HS_MITF; -.
DR   ExpressionAtlas; O75030; baseline and differential.
DR   Genevisible; O75030; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; NAS:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II core promoter proximal region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0001077; F:RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription; IDA:UniProtKB.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0003705; F:RNA polymerase II distal enhancer sequence-specific DNA binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:0001227; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding transcription factor activity involved in negative regulation of transcription; NAS:BHF-UCL.
DR   GO; GO:0046849; P:bone remodeling; IEA:Ensembl.
DR   GO; GO:0043010; P:camera-type eye development; IEA:Ensembl.
DR   GO; GO:0044336; P:canonical Wnt signaling pathway involved in negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0045165; P:cell fate commitment; IEA:Ensembl.
DR   GO; GO:0097531; P:mast cell migration; IEA:InterPro.
DR   GO; GO:0030318; P:melanocyte differentiation; NAS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0030316; P:osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:2000144; P:positive regulation of DNA-templated transcription, initiation; IDA:CACAO.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:CACAO.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0006461; P:protein complex assembly; IDA:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0045670; P:regulation of osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:2001141; P:regulation of RNA biosynthetic process; IDA:CACAO.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR021802; bHLH_ZIP_TF_MiT/TFE.
DR   InterPro; IPR030532; MITF.
DR   PANTHER; PTHR10014:SF38; PTHR10014:SF38; 1.
DR   Pfam; PF11851; DUF3371; 1.
DR   Pfam; PF00010; HLH; 1.
DR   SMART; SM00353; HLH; 1.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   PROSITE; PS50888; BHLH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Albinism; Alternative splicing;
KW   Complete proteome; Deafness; Developmental protein; Disease mutation;
KW   DNA-binding; Isopeptide bond; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transcription; Transcription regulation;
KW   Ubl conjugation; Waardenburg syndrome.
FT   CHAIN         1    526       Microphthalmia-associated transcription
FT                                factor.
FT                                /FTId=PRO_0000127276.
FT   DOMAIN      311    364       bHLH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00981}.
FT   REGION      224    295       Transactivation.
FT   REGION      374    395       Leucine-zipper.
FT   REGION      401    431       DNA binding regulation.
FT   MOD_RES     180    180       Phosphoserine; by MAPK.
FT                                {ECO:0000269|PubMed:10673502}.
FT   MOD_RES     405    405       Phosphoserine; by GSK3.
FT                                {ECO:0000269|PubMed:10587587}.
FT   MOD_RES     414    414       Phosphoserine.
FT                                {ECO:0000269|PubMed:18220336,
FT                                ECO:0000269|PubMed:18669648}.
FT   MOD_RES     491    491       Phosphoserine.
FT                                {ECO:0000269|PubMed:20068231}.
FT   MOD_RES     516    516       Phosphoserine; by RPS6KA1.
FT                                {ECO:0000269|PubMed:10673502}.
FT   CROSSLNK    289    289       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   CROSSLNK    423    423       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   VAR_SEQ       1    118       MQSESGIVPDFEVGEEFHEEPKTYYELKSQPLKSSSSAEHP
FT                                GASKPPISSSSMTSRILLRQQLMREQMQEQERREQQQKLQA
FT                                AQFMQQRVPVSQTPAINVSVPTTLPSATQVPMEVLK -> M
FT                                LEMLEYNHYQ (in isoform M1, isoform M2 and
FT                                isoform Mdel).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:20163701,
FT                                ECO:0000303|PubMed:8069297}.
FT                                /FTId=VSP_002127.
FT   VAR_SEQ       1     52       Missing (in isoform 12).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046438.
FT   VAR_SEQ       1     35       MQSESGIVPDFEVGEEFHEEPKTYYELKSQPLKSS -> ME
FT                                ALRVQMFMPCSFESLYL (in isoform H1 and
FT                                isoform H2). {ECO:0000305}.
FT                                /FTId=VSP_002126.
FT   VAR_SEQ       1     34       MQSESGIVPDFEVGEEFHEEPKTYYELKSQPLKS -> MLY
FT                                AFWFSH (in isoform B1 and isoform B2).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_002124.
FT   VAR_SEQ       1     34       MQSESGIVPDFEVGEEFHEEPKTYYELKSQPLKS -> MGH
FT                                LENTSVVFPRAIFSLCEKETRKLTLCLFSR (in
FT                                isoform C1 and isoform C2).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_002125.
FT   VAR_SEQ     139    194       Missing (in isoform Mdel).
FT                                {ECO:0000303|PubMed:20163701}.
FT                                /FTId=VSP_045178.
FT   VAR_SEQ     293    298       Missing (in isoform Mdel and isoform 12).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:20163701}.
FT                                /FTId=VSP_045179.
FT   VAR_SEQ     294    299       Missing (in isoform A2, isoform B2,
FT                                isoform C2, isoform H2 and isoform M2).
FT                                {ECO:0000303|PubMed:11230166,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9647758}.
FT                                /FTId=VSP_002128.
FT   VARIANT     310    310       R -> K (in WS2A; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:8589691}.
FT                                /FTId=VAR_010297.
FT   VARIANT     317    317       N -> K (in TIETZS).
FT                                {ECO:0000269|PubMed:10851256}.
FT                                /FTId=VAR_010298.
FT   VARIANT     324    324       Missing (in WS2A).
FT                                {ECO:0000269|PubMed:8589691}.
FT                                /FTId=VAR_010299.
FT   VARIANT     357    357       S -> P (in WS2A).
FT                                {ECO:0000269|PubMed:8589691}.
FT                                /FTId=VAR_010300.
FT   VARIANT     385    385       N -> D (in WS2A).
FT                                {ECO:0000269|PubMed:8589691}.
FT                                /FTId=VAR_010301.
FT   VARIANT     405    405       S -> P (in WS2A).
FT                                {ECO:0000269|PubMed:8589691}.
FT                                /FTId=VAR_010302.
FT   VARIANT     425    425       E -> K (may be associated with
FT                                susceptibility to CMM8; has increased
FT                                frequency in individuals with melanoma or
FT                                renal cell carcinoma compared to
FT                                controls; affects sumoylation;
FT                                dbSNP:rs149617956).
FT                                {ECO:0000269|PubMed:22012259,
FT                                ECO:0000269|PubMed:22080950}.
FT                                /FTId=VAR_067367.
FT   MUTAGEN     180    180       S->A: Abolishes both transcription factor
FT                                activity and ubiquitination, leading to
FT                                an inert and stable protein; when
FT                                associated with A-516.
FT                                {ECO:0000269|PubMed:10673502}.
FT   MUTAGEN     289    289       K->R: Loss of sumoylation; when
FT                                associated with R-423.
FT                                {ECO:0000269|PubMed:15507434}.
FT   MUTAGEN     405    405       S->A,P: Loss of phosphorylation and
FT                                function. {ECO:0000269|PubMed:10587587}.
FT   MUTAGEN     423    423       K->R: Loss of sumoylation; when
FT                                associated with R-289.
FT                                {ECO:0000269|PubMed:15507434}.
FT   MUTAGEN     516    516       S->A: Abolishes both transcription factor
FT                                activity and ubiquitination, leading to
FT                                an inert and stable protein; when
FT                                associated with A-180.
FT                                {ECO:0000269|PubMed:10673502}.
FT   CONFLICT    241    241       I -> T (in Ref. 5; BAG58874).
FT                                {ECO:0000305}.
FT   HELIX       357    401       {ECO:0000244|PDB:4C7N}.
SQ   SEQUENCE   526 AA;  58795 MW;  136EBED3044C1986 CRC64;
     MQSESGIVPD FEVGEEFHEE PKTYYELKSQ PLKSSSSAEH PGASKPPISS SSMTSRILLR
     QQLMREQMQE QERREQQQKL QAAQFMQQRV PVSQTPAINV SVPTTLPSAT QVPMEVLKVQ
     THLENPTKYH IQQAQRQQVK QYLSTTLANK HANQVLSLPC PNQPGDHVMP PVPGSSAPNS
     PMAMLTLNSN CEKEGFYKFE EQNRAESECP GMNTHSRASC MQMDDVIDDI ISLESSYNEE
     ILGLMDPALQ MANTLPVSGN LIDLYGNQGL PPPGLTISNS CPANLPNIKR ELTACIFPTE
     SEARALAKER QKKDNHNLIE RRRRFNINDR IKELGTLIPK SNDPDMRWNK GTILKASVDY
     IRKLQREQQR AKELENRQKK LEHANRHLLL RIQELEMQAR AHGLSLIPST GLCSPDLVNR
     IIKQEPVLEN CSQDLLQHHA DLTCTTTLDL TDGTITFNNN LGTGTEANQA YSVPTKMGSK
     LEDILMDDTL SPVGVTDPLL SSVSPGASKT SSRRSSMSME ETEHTC
//
